Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tenofovir Disoproxil Fumarate.
- Who it may be relevant to
- Registry conditions: Parkinson Disease. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Overview
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Interventions
- Drug Tenofovir Disoproxil Fumarate
take tenofovir disoproxil fumarate 300mg/d
Primary outcome measures
- UPDRS III（Unified Parkinson's Disease Rating Scale part 3） [Time frame: 1 month、3 month]
Secondary outcome measures (2)
- Non-Motor Symptom Scale（NMSS） [Time frame: 1 month、3 month]
- creatinine(μmoI/L) [Time frame: 1 month、3 month]
Eligibility criteria
Inclusion criteria
- 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24
Exclusion criteria
- 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders
2: Or have received deep brain stimulation and other brain surgery
3: Abnormal liver and kidney function
4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)
5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence
6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor
7: Pregnant or lactating women and seniors over 65 years of age
8: Allergy or other contraindications to the investigational drug
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Guohua Zhao — Hangzhou
Identifiers
NCT: NCT06356662 · KY-2023-198